Glioblastoma
February 2018 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Glioblastoma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Glioblastoma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Glioblastoma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Glioblastoma every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Authors:Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran DD, Brem S, Hottinger AF, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Burna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z
Institution:Lou and Jean MalnatiBrain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Feinberg School of Medicine, Chicago, Illinois. Switzerland. 1127, Institut du Cerveau et de la Moelle epiniere, ICM, F-75013, Paris, France. Switzerland. 1127, Institut du Cerveau et de la Moelle epiniere, ICM, F-75013, Paris, France. Switzerland. Medicine, Bundang, Korea. Switzerland.
Journal:JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718.

2:Review of Natural Product-Derived Compounds as Potent Antiglioblastoma Drugs.
Authors:Park MN, Song HS, Kim M, Lee MJ, Cho W, Lee HJ, Hwang CH, Kim S, Hwang Y, Kang B, Kim B
Institution:College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. School, Kyung Hee University, Seoul, Republic of Korea.
Journal:Biomed Res Int. 2017;2017:8139848. doi: 10.1155/2017/8139848. Epub 2017 Oct 18.

3:Lomustine and Bevacizumab in Progressive Glioblastoma.
Authors:Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ
Institution:From the University Medical Center and German Cancer Research Center, Heidelberg, Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B., M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.); Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris, Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau, Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R., F.D.) - all in France; and the Departments of Oncology and Neurology, University Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
Journal:N Engl J Med. 2017 Nov 16;377(20):1954-1963. doi: 10.1056/NEJMoa1707358.

4:Pseudoprogression as an adverse event of glioblastoma therapy.
Authors:Balana C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-Garcia M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villa S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F
Institution:Medical Oncology, Institut Catala Oncologia (ICO), Badalona, Barcelona, Spain. Research Institute (IDIBGI), Hospital Universitari Dr Josep Trueta, Girona, Spain. LLobregat, Barcelona, Spain. Barcelona, Spain. LLobregat, Barcelona, Spain.
Journal:Cancer Med. 2017 Dec;6(12):2858-2866. doi: 10.1002/cam4.1242. Epub 2017 Nov 3.

5:Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.
Authors:Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, Souhami L, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, Werner-Wasik M
Institution:Sidney Kimmel Cancer Center and Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania. Illinois. Philadelphia, Pennsylvania. Foundation, Phoenix, Arizona. Illinois; NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania. Philadelphia, Pennsylvania. Electronic address: maria.werner-wasik@jefferson.edu.
Journal:Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):38-44. doi: 10.1016/j.ijrobp.2017.08.038. Epub 2017 Sep 4.

6:A comparison between oral chemotherapy combined with radiotherapy and radiotherapy for newly diagnosed glioblastoma: A systematic review and meta-analysis.
Authors:Wang Z, Yang G, Zhang YY, Yao Y, Dong LH
Institution:aDepartment of Radiotherapy, Norman Bethune First Hospital bDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, China.
Journal:Medicine (Baltimore). 2017 Nov;96(44):e8444. doi: 10.1097/MD.0000000000008444.

7:Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
Authors:van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA
Institution:Brain Tumor Center, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, the Netherlands. m.vandenbent@erasmusmc.nl. University Medical Center, New York, NY, USA. Francisco, CA, USA. Royal Brisbane and Women's Hospital, Brisbane, Australia.
Journal:Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26.

8:Treatment of Glioblastoma.
Authors:Nam JY, de Groot JF
Institution:The University of Texas MD Anderson Cancer Center, Houston, TX.
Journal:J Oncol Pract. 2017 Oct;13(10):629-638. doi: 10.1200/JOP.2017.025536.

9:Prognostication of Survival Outcomes in Patients Diagnosed with Glioblastoma.
Authors:Nizamutdinov D, Stock EM, Dandashi JA, Vasquez EA, Mao Y, Dayawansa S, Zhang J, Wu E, Fonkem E, Huang JH
Institution:Texas A&M Health Science Center College of Medicine, Temple, Texas, USA; Department of Neurosurgery, Baylor Scott and White Health Care, Temple, Texas, USA. System, Perry Point, Maryland, USA. Department of Neurosurgery, Baylor Scott and White Health Care, Temple, Texas, USA. USA. Department of Neurosurgery, Baylor Scott and White Health Care, Temple, Texas, USA. Department of Neurosurgery, Baylor Scott and White Health Care, Temple, Texas, USA. Electronic address: Jason.Huang@bswhealth.org.
Journal:World Neurosurg. 2018 Jan;109:e67-e74. doi: 10.1016/j.wneu.2017.09.104. Epub 2017 Sep 23.

10:Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Authors:Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH
Institution:Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland. Electronic address: michael.weller@usz.ch. USA. Pennsylvania, Philadelphia, PA, USA. Neurosurgery, Foothills Hospital, Calgary, AB, Canada. Germany. Switzerland. Durham, NC, USA.
Journal:Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23.

11:Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Authors:Badruddoja MA, Pazzi M, Sanan A, Schroeder K, Kuzma K, Norton T, Scully T, Mahadevan D, Ahmadi MM
Institution:Center for Neurosciences, 2450 E River Rd, Tucson, AZ, 85718, USA. badru001@neurotucson.com. Campbell Avenue, Tucson, AZ, 85724, USA. badru001@neurotucson.com.
Journal:Cancer Chemother Pharmacol. 2017 Oct;80(4):715-721. doi: 10.1007/s00280-017-3405-7. Epub 2017 Aug 14.

12:Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles.
Authors:Miranda A, Blanco-Prieto MJ, Sousa J, Pais A, Vitorino C
Institution:Faculty of Pharmacy, University of Coimbra, Portugal; Pharmacometrics Group of the Centre for Neurosciences and Cell Biology (CNC), University of Coimbra, Portugal. Electronic address: csvitorino@ff.uc.pt.; Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra, IdiSNA, Pamplona, Spain.; Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, Portugal.
Journal:Int J Pharm. 2017 Oct 5;531(1):389-410. doi: 10.1016/j.ijpharm.2017.07.049. Epub 2017 Aug 9.

13:Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
Authors:Miranda A, Blanco-Prieto M, Sousa J, Pais A, Vitorino C
Institution:Faculty of Pharmacy, University of Coimbra, Portugal; Pharmacometrics Group of the Centre for Neurosciences and Cell Biology (CNC), University of Coimbra, Portugal. Electronic address: csvitorino@ff.uc.pt.; Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Spain.; Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, Portugal.
Journal:Int J Pharm. 2017 Oct 5;531(1):372-388. doi: 10.1016/j.ijpharm.2017.07.056. Epub 2017 Jul 27.

14:Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.
Authors:Gan HK, van den Bent M, Lassman AB, Reardon DA, Scott AM
Institution:Austin Health and Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Victoria 3084, Australia. Victoria 3084, Australia. Victoria 3084, Australia. Rotterdam, Netherlands. University Medical Center, 161 Fort Washington Avenue, New York, New York 10032, USA. Massachusetts 02215, USA. Heidelberg, Victoria 3084, Australia. Victoria 3084, Australia. Victoria 3084, Australia.
Journal:Nat Rev Clin Oncol. 2017 Nov;14(11):695-707. doi: 10.1038/nrclinonc.2017.95. Epub 2017 Jul 4.

15:Clinical and Molecular Prognostic Factors for Long-Term Survival of Patients with Glioblastomas in Single-Institutional Consecutive Cohort.
Authors:Nakagawa Y, Sasaki H, Ohara K, Ezaki T, Toda M, Ohira T, Kawase T, Yoshida K
Institution:Department of Neurosurgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. Electronic address: hsasaki@a5.keio.jp.; Department of Pathology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Journal:World Neurosurg. 2017 Oct;106:165-173. doi: 10.1016/j.wneu.2017.06.126. Epub 2017 Jun 27.

For a FREE PREVIEW of the Medifocus Guidebook on Glioblastoma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Glioblastoma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Glioblastoma...
at a Special 20% Discount


Medifocus Guidebook on Glioblastoma

Updated: January 15, 2018
164 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Glioblastoma is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

GL42863763

Coupon Expires: March 24, 2018



What Our Customers Are Saying...

"To be diagnosed with a glioblastoma is devastating news. The MediFocus Guidebook on Glioblastoma clearly explained medical terms and adopted a positive approach although not discounting the problems."
E.S.
London, England


"Your Guidebook was EXTREMELY helpful and full of valuable information. I was able to understand "doctor language" and sound educated myself. It was well worth the price."
D.S.
Fairview, Tennessee


"I had never heard of Glioblastoma until one of my relatives was diagnosed with it and was given a very pessimistic outlook. Your Guidebook provided me with the background and sources of additional information necessary to allow me to be of help to him as he decided on his treatment options."
R.W.R.
Pittsfield, Massachusetts



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.